| 0 (0%) | 01-14 09:37 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 35.31  |
1-year : | 37.72 |
| Resists | First : | 30.23 |
Second : | 32.3 |
| Pivot price | 29.81 |
|||
| Supports | First : | 26.88 |
Second : | 22.37 |
| MAs | MA(5) : | 28.97 |
MA(20) : | 30.07 |
| MA(100) : | 32.21 |
MA(250) : | 34.1 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 13 |
D(3) : | 27.5 |
| RSI | RSI(14): 35.2  |
|||
| 52-week | High : | 46.47 | Low : | 25.28 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TGTX ] has closed above bottom band by 3.9%. Bollinger Bands are 0.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 28.92 - 29.07 | 29.07 - 29.21 |
| Low: | 26.57 - 26.71 | 26.71 - 26.85 |
| Close: | 27.64 - 27.87 | 27.87 - 28.1 |
Wed, 14 Jan 2026
Why TG Therapeutics Stock Is Moving Today - Benzinga
Wed, 14 Jan 2026
TG Therapeutics Stock Pre-Market (+7.0%) : Strong 2026 Revenue Guidance Issued - Trefis
Tue, 13 Jan 2026
After-Hours Biotech Rally: SXTC, RPID, TGTX Lead Gains On Revenue Updates, And FDA Milestones - Nasdaq
Tue, 13 Jan 2026
TG Therapeutics (TGTX) Projects Strong Revenue Growth for 2026 - GuruFocus
Tue, 13 Jan 2026
TGTX Rallies 7% After Hours On Revenue Estimates Based On Strong Briumvi Demand Through 2026 - Stocktwits
Tue, 13 Jan 2026
TGTX rallies 8% after hours on revenue estimates based on strong Briumvi demand through 2026 - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 159 (M) |
| Held by Insiders | 1.4039e+008 (%) |
| Held by Institutions | 6.7 (%) |
| Shares Short | 25,220 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 2.76 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 50 |
| Profit Margin | 84.1 % |
| Operating Margin | 18.1 % |
| Return on Assets (ttm) | 7.9 % |
| Return on Equity (ttm) | 111.9 % |
| Qtrly Rev. Growth | 92.8 % |
| Gross Profit (p.s.) | 2.25836e+008 |
| Sales Per Share | 2.64627e+008 |
| EBITDA (p.s.) | 5.11592e+007 |
| Qtrly Earnings Growth | 12 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -70 (M) |
| PE Ratio | 10.06 |
| PEG Ratio | 0 |
| Price to Book value | 0.55 |
| Price to Sales | 0 |
| Price to Cash Flow | 13.14 |
| Dividend | 0 |
| Forward Dividend | 2.511e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|